Table 3.

Association of rs7512462 with CFTR modulator response.

Studies	Covariates	Effect Size	S.E.	P-value
IVA(CGMS)	Age at baseline	–0.077	0.095	0.419
	FEV1pp at baseline	–0.025	0.073	0.731
	rs7512462_CC	9.905	4.477	0.033
	Early CGMS Cohort	5.336	2.606	0.047
LUM/IVA (US PROSPECT)	Age at baseline	–0.188	0.074	0.014
	FEV1pp at baseline	–0.123	0.053	0.024
	rs7512462_CC	8.518	2.657	0.002
LUM/IVA (US PROSPECT + CGMS)	Age at baseline	–0.119	0.064	0.066
	FEV1pp at baseline	–0.069	0.037	0.066
	rs7512462_CC	5.217	1.871	0.006
	PROSPECT Cohort	0.865	1.401	0.540

CFTR modulator response is the difference between the FEV_1pp after the modulator response and the value at last visit before the treatment initiation within 3 months as defined in Methods. Increased Δ FEV_1pp indicates better treatment response. Sample sizes in each CFTR modulator treatment group are n = 45 for IVA (CGMS), n = 91 for LUM/IVA (US PROSPECT) and n = 195 for the combined LUM/IVA analysis of the US PROSPECT and CGMS participants (US PROSPECT + CGMS). Early CGMS Cohort for IVA-CGMS reflects an indicator for those participants that were included in an earlier published study³¹. LUM/IVA studies were also adjusted for population structure by principal components (PCs; n = 7 PCs for US PROSPECT and n = 4 for US PROSPECT + CGMS). PROSPECT Cohort is an indicator of whether the individual was a participant in the US PROSPECT study or the CGMS. All results use robust variance estimates.